TopFunds

Baxter International

NYSE: BAX

Stock price

22.54 USD

(+0%) TODAY

Health Care EquipmentMedical - Instruments & Supplies
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
1.8
9
1.1
3
1.9
2.1
2.5
(4.8)
5.2
(1.3)
(1.7)
-
02Free cash flow per share
1.6
1.7
2
2.5
2.7
2.2
3
1.1
2.5
1.1
0.6
(8.7)%
03Dividends per share
0.8
0.5
0.6
0.7
0.9
1
1.1
1.2
1.2
1
0.5
(4.2)%
04Dividends payout, %
94%
5.4%
52.3%
24.3%
42.3%
42.9%
41.3%
(23.6)%
22.1%
(90.9)%
(36.4)%
-
PROFIT AND LOSS STATEMENT
05Revenue
$ 9,968
$ 10,163
$ 10,584
$ 11,099
$ 11,362
$ 11,673
$ 12,146
$ 10,057
$ 10,360
$ 10,636
$ 11,244
1.2%
06% Change
-
2%
4.1%
4.9%
2.4%
2.7%
4.1%
(17.2)%
3%
2.7%
5.7%
1.2%
07Cost of revenue
(5,822)
(6,047)
(6,110)
(6,340)
(6,601)
(7,086)
(7,426)
(6,508)
(6,210)
(6,652)
(7,865)
3.1%
08Gross profit
4,146
4,116
4,474
4,759
4,761
4,587
4,720
3,549
4,150
3,984
3,379
(2)%
09% Margin
41.6%
40.5%
42.3%
42.9%
41.9%
39.3%
38.9%
35.3%
40.1%
37.5%
30.1%
39.1% A
10Operating expenses
(3,697)
(3,371)
(3,186)
(3,175)
(2,989)
(2,971)
(3,370)
(6,394)
(3,443)
(3,970)
(3,687)
(0)%
11% of Revenue
(37.1)%
(33.2)%
(30.1)%
(28.6)%
(26.3)%
(25.5)%
(27.8)%
(63.6)%
(33.2)%
(37.3)%
(32.8)%
(34.1)% A
12Operating Income
449
745
1,288
1,584
1,772
1,616
1,350
(2,845)
707
14
(308)
-
13Income tax expense
(35)
(12)
(491)
(65)
(41)
(182)
(83)
(135)
(61)
(37)
(395)
27.4%
14Net Income
968
4,965
602
1,546
1,001
1,102
1,284
(2,433)
2,656
(649)
(957)
-
15% Margin
9.7%
48.9%
5.7%
13.9%
8.8%
9.4%
10.6%
(24.2)%
25.6%
(6.1)%
(8.5)%
8.5% A
16Shares Outstanding
549,000
551,000
555,000
546,000
519,000
517,000
508,000
504,000
506,000
510,000
513,000
(0.7)%
17EPS Basic
1.8
9.1
1.1
3
2
2.2
2.6
(4.8)
5.3
(1.3)
(1.7)
-
18EPS Diluted
1.8
9
1.1
3
1.9
2.1
2.5
(4.8)
5.2
(1.3)
(1.7)
-
19EBITDA
1,333
5,843
1,935
2,481
1,870
2,268
2,190
(1,763)
1,734
1,116
766
(5.4)%
% Margin
13.4%
57.5%
18.3%
22.4%
16.5%
19.4%
18%
(17.5)%
16.7%
10.5%
6.8%
16.5% A
20Net Interest Income (expense)
(126)
(66)
(55)
(45)
(71)
(134)
(193)
(394)
(439)
(341)
(238)
6.6%
21Net Debt / EBITDA
3.2
-
0.1
0.7
1.4
1.4
7
(8.8)
6.4
10.5
10.5
2.9 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
2,213
2,801
3,394
1,838
3,335
3,730
2,951
1,718
3,078
1,764
1,966
(1.2)%
23Short-term investments
5,148
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
1,731
1,691
1,793
1,840
1,896
2,077
2,713
2,623
1,772
1,730
1,932
1.1%
25Other current assets
1,100
652
601
614
619
688
755
991
2,832
3,313
740
(3.9)%
26Inventory
1,604
1,430
1,475
1,667
1,653
1,916
2,453
2,679
1,918
2,046
2,232
3.4%
27Total Current Assets
11,796
6,574
7,263
5,959
7,503
8,411
8,872
8,011
9,600
8,853
6,872
(5.3)%
Non-Current Assets
28Net property, plant & equipment
4,386
4,289
4,588
4,530
5,120
5,325
5,808
5,236
3,207
3,176
3,186
(3.2)%
29Long-term investments
-
-
-
44
76
135
195
247
136
109
103
-
30Other non-current assets
4,780
4,683
5,260
5,187
5,494
6,148
18,646
14,793
15,333
13,644
9,894
7.6%
31Total Non-Current Assets
9,166
8,972
9,848
9,761
10,690
11,608
24,649
20,276
18,676
16,929
13,183
3.7%
Total Assets
20,962
15,546
17,111
15,720
18,193
20,019
33,521
28,287
28,276
25,782
20,055
(0.4)%
LIABILITIES
Current Liabilities
32Accounts payable
716
791
920
998
892
1,043
1,246
1,110
881
968
999
3.4%
33Short-term debt
2,585
3
3
4
642
517
639
1,524
2,759
2,832
84
(29)%
34Other current liabilities
2,449
1,950
1,898
1,812
1,696
1,773
2,351
2,111
2,863
2,711
1,887
(2.6)%
35Total Current Liabilities
5,750
2,744
2,821
2,814
3,230
3,333
4,236
4,745
6,503
6,511
2,970
(6.4)%
Non-Current Liabilities
36Long-term debt
3,922
2,779
3,509
3,481
5,319
6,287
17,671
15,679
11,354
10,617
9,919
9.7%
37Other non-current liabilities
2,425
1,743
1,665
1,559
1,732
1,673
2,493
1,968
1,951
1,630
1,064
(7.9)%
38Total Non-Current Liabilities
6,347
4,522
5,174
5,040
7,051
7,960
20,164
17,647
13,305
12,247
10,983
5.6%
39Total Liabilities
12,097
7,266
7,995
7,854
10,281
11,293
24,400
22,392
19,808
18,758
13,953
1.4%
SHAREHOLDERS` EQUITY
40Common stock
683
683
683
683
683
683
683
683
683
683
683
-
41Retained earnings / (deficit)
9,683
14,200
14,483
15,075
15,718
16,328
17,065
14,050
16,114
14,929
13,705
3.5%
42Accumulated other comprehensive income / (loss)
224
(4,556)
(4,001)
(3,823)
(3,710)
(3,314)
(3,380)
(3,833)
(3,554)
(4,010)
(3,754)
-
43Noncontrolling interests
19
(10)
(8)
22
30
37
44
62
66
60
(27)
-
44Total shareholders' equity
8,865
8,280
9,116
7,866
7,912
8,726
9,121
5,895
8,468
7,024
6,102
(3.7)%
45Total Liabilities and shareholders' Equity
20,962
15,546
17,111
15,720
18,193
20,019
33,521
28,287
28,276
25,782
20,055
(0.4)%
46Total Debt
6,507
2,782
3,512
3,485
5,961
6,804
18,310
17,203
14,113
13,449
10,003
4.4%
47Net Debt
4,294
(19)
118
1,647
2,626
3,074
15,359
15,485
11,035
11,685
8,037
6.5%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
968
4,965
602
1,546
1,001
1,102
1,284
(2,433)
2,656
(649)
(957)
-
49Depreciation & amortization
759
800
750
771
789
823
867
1,072
984
997
981
2.6%
50Share-based compensation expense
126
115
107
115
122
130
146
140
115
114
117
(0.7)%
51Changes in working capital and other assets
(82)
(4,226)
255
(415)
192
(187)
(75)
2,432
(2,029)
557
704
-
52Net cash flows from operating activities
1,771
1,654
1,714
2,017
2,104
1,868
2,222
1,211
1,726
1,019
845
(7.1)%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(911)
(719)
(616)
(659)
(696)
(709)
(691)
(635)
(436)
(460)
(513)
(5.6)%
54Purchases of investments / marketable securities
-
(48)
-
-
-
-
-
-
-
-
-
-
55Proceeds from maturities of marketable securities
-
-
-
-
-
-
-
-
-
34
-
-
56Other investing activities
(896)
52
(676)
(257)
(404)
(470)
(10,509)
(296)
3,649
(200)
3,354
-
57Net cash flows from investing activities
(1,807)
(715)
(1,292)
(916)
(1,100)
(1,179)
(11,200)
(931)
3,213
(626)
2,841
-
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
-
(292)
(564)
(2,452)
(1,270)
(500)
(413)
95
95
71
30
-
59Dividends paid, net
(910)
(268)
(315)
(376)
(423)
(473)
(530)
(573)
(586)
(590)
(348)
(9.2)%
60Debt issuance (repayments), net
2,393
(56)
665
-
1,883
478
9,326
(899)
(2,935)
(531)
(3,791)
-
61Other financing activities
(1,964)
292
307
225
308
150
(138)
(61)
(63)
(31)
(107)
(25.3)%
62Net cash flows from financing activities
(481)
(324)
93
(2,603)
498
(345)
8,245
(1,438)
(3,489)
(1,081)
(4,216)
24.2%
63Increase (decrease) in cash and cash equivalents
(712)
588
617
(1,565)
1,497
401
(780)
(1,234)
1,476
(784)
(446)
(4.6)%
64Cash and equivalents, ending balance
2,213
2,801
3,403
1,838
3,335
3,736
2,956
1,722
3,198
2,414
1,968
(1.2)%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
860
935
1,098
1,358
1,408
1,159
1,531
576
1,290
559
332
(9.1)%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Baxter International (BAX) financial statements and performance

Explore Baxter International (BAX) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.